P3781
TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated DonorsDonor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched DonorsStudy of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant PatientsHaplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction ChemotherapyAllogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood DiseasesPurged Circulating Tumor Cells (CTCs) From Metastatic Breast CancerClofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other DiseaseIntensified IAA With PBPC Support in Breast Tumors With Evidence of a HRDCombination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell LymphomaAuto Transplant for High Risk or Relapsed Solid or CNS TumorsVorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous SystemT-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other AnemiasTotal-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerAlemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerChemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem TumorsHigh-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast CancerPeripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast CancerCombination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian CancerRadiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic LeukemiaRadiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal TumorsBiological Therapy in Treating Women With Metastatic Breast CancerCombination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With OligodendrogliomaConditioning Regimen for Allogeneic Hematopoietic Stem-Cell TransplantationConditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic LeukaemiaALL-SCT BFM International- HSCT in Children and Adolescents With ALLBone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two StepsAutologous Stem Cell Transplantation in Patients With Systemic SclerosisLung and Bone Marrow Transplantation for Lung and Bone Marrow FailureRandomized Double Cord Blood Transplant StudyCombination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic CancerVPA Expanded UCB Transplantation for Treatment of Patients With Hematological MalignanciesComparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk NeuroblastomaDinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell TransplantNaive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell TransplantPeripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With PosaconazoleSelective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHDMyeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
P4844
Q61904950-93460E06-0088-4E4B-AAAF-686CB72DE517Q61904952-6178161E-505F-4A2B-AC90-71427E43FF4CQ61906925-95C4FF18-7751-427D-AB8F-A6AA1673C17BQ61907988-0C13584B-22CB-44DF-9330-3208D8844BF5Q61908819-6C3C41A8-7641-4249-B814-2F33DD8E82D9Q61914538-AD35C1E1-6D93-4361-A0D1-4BA3E7866467Q61921024-B1A78546-2F50-43E2-B32E-E52372501FF6Q61921209-DBB1006B-54FF-4BC3-AA43-206B25062A72Q61921685-5170D040-3B6D-43BE-8EF4-D0C98EEA9D28Q61923859-9135E4C9-0CFA-43C9-9C4C-D113708915E2Q61956013-EEE25EE6-36CD-4010-BFDA-284A0CAE391BQ61957088-4A1244FE-7573-42F0-B342-576AFA33FF14Q61980918-FF7CC425-54D1-46A9-ADC9-01C402F98A52Q62025171-AC908689-1F16-4A44-93D4-82ECEBB92944Q62105040-F2E07CE4-0468-497F-BA95-24174ED90FB5Q62105821-7DA3E0BF-7E9B-484C-A137-62815FC54463Q62110031-3E22995B-8E07-40DF-A54C-313E0B09BD4EQ62110187-C8BD7720-D940-4438-9733-627E91955D12Q62110369-BA0C6E98-E381-4B0B-90C1-FD067B87CDCCQ62110494-59AEBCFF-2CE3-4F61-B985-6F79E9D05C7CQ62110532-DFFEF5A7-F526-49E8-BFE9-06FCC4C99CFBQ62110968-9E79EE59-3A54-41ED-BE68-AF5A777D9150Q62110998-BD5A19B9-30E2-4908-BEC0-670A4B79BC13Q62111030-44077AAA-4E6E-4AE7-AD01-6BB9D97B9F7AQ62819286-16D62391-4F16-4CB1-9B92-7C983AEF8A01Q63062982-93BF7C76-862D-4BEC-BD8A-B247DBD728BEQ63321644-17785854-3032-42C1-A3FB-AC801570C43AQ63321701-2FD2E7A5-515A-4DFA-AE0F-04AC1EC6E8C4Q63334869-A8A49874-B134-4DB8-8F0E-C2B552EBAF05Q63395024-EEDA9E08-3980-4DB3-8E5E-A15039A237ACQ63399177-AA55225D-1552-4A0D-9399-E1CBF7704D1CQ63577593-E7558E24-4308-4084-A5BB-0C2B596F8E9AQ63577640-253531D7-B70B-4487-AD75-529756C6DFC7Q63581672-B6262E55-EA70-457C-9E2B-378293221053Q63591257-89B38FE5-43C8-4DDE-8C1E-B74A58CACE6BQ63591834-68C2FDD1-9DE5-4EA5-99DA-542433446FAAQ63594642-6245F117-E09B-48AF-8684-1B96E23AF326Q63613411-69E12093-5F5C-4B7C-BB0F-C450202B7A0CQ63807952-1357AC54-C4F4-488A-9278-E82D9F1A65EAQ63813364-DA748BB7-9D5A-4BBA-981B-3411223E8261
P4844
description
Agente alquilante
@es
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
name
ThioTEPA
@cy
Thiotepa
@de
Thiotepa
@fr
Thiotepa
@nl
Thiotepa
@vi
TioTEPA
@sh
TioTEPA
@sr
Tiotepa
@es
Tiotepa
@fi
Tiotepa
@it
type
label
ThioTEPA
@cy
Thiotepa
@de
Thiotepa
@fr
Thiotepa
@nl
Thiotepa
@vi
TioTEPA
@sh
TioTEPA
@sr
Tiotepa
@es
Tiotepa
@fi
Tiotepa
@it
altLabel
Tepadina
@it
Tepadina®
@cy
Tepadina®
@en
ThioTEPA 或 thiotepa
@cy
ThioTEPA 或 thiotepa
@en
ThioTEPA
@pl
Thioplex®
@cy
Thioplex®
@en
Thiotepa
@en
Thiotepa
@it
prefLabel
ThioTEPA
@cy
Thiotepa
@de
Thiotepa
@fr
Thiotepa
@nl
Thiotepa
@vi
TioTEPA
@sh
TioTEPA
@sr
Tiotepa
@es
Tiotepa
@fi
Tiotepa
@it